Dietary Patterns for Coronary Atherosclerosis: Separating Evidence for Plaque Regression from Evidence for Cardiovascular Event Reduction

An Author-Derived Two-Ladder Framework and Evidence-Graded Narrative Review of Plant-Predominant, Mediterranean, Portfolio, and DASH Dietary Patterns

Key message

Coronary atherosclerosis is primarily driven by cumulative exposure to ApoB-containing lipoproteins, with diet the major modifiable lifelong determinant in most populations: human migrant and cohort studies indicate that its lifetime incidence tracks lifelong exposure to atherogenic, ApoB-raising diets, which makes diet the principal modifiable lifelong lever in most populations. The disease’s dangerous, lipid-rich, rupture-prone compartment is also its most regressible one, and controlled primate experiments show that normalizing the atherogenic-lipoprotein burden depletes and stabilizes exactly that compartment. Diet and ApoB-lowering drugs act on the same shared mechanism — diet at the cause across a lifetime, drugs potently from mid-life — and are complementary levers rather than competitors. The convergent, low-risk conclusion is the same throughout: shift the diet toward whole plants.

Abstract

Coronary atherosclerosis is primarily driven by cumulative exposure to apolipoprotein B-containing lipoproteins, with diet the major modifiable lifelong determinant in most populations; this narrative review asks what that causal framing does and does not imply for reversing established disease. Using a two-ladder framework that separates evidence for favorable change on arterial imaging from evidence for reducing hard cardiovascular events, and grading each body of evidence for certainty, we synthesize migrant, cohort, primate, imaging, pharmacologic, and dietary-trial data. Population and genetic evidence support diet as a major determinant of lifelong ApoB exposure. Controlled primate work shows that normalizing the atherogenic-lipoprotein burden depletes and stabilizes the rupture-prone, lipid-rich necrotic core while dense fibrocalcific tissue persists. Because outward and constrictive remodeling make lumen and stenosis unreliable endpoints, the event-relevant change is compositional rather than luminal. Mediterranean-style patterns carry the strongest randomized hard-event evidence among named diets, whereas lipid-lowering pharmacotherapy retains the most reproducible imaging-regression data; exercise is a genuine but modest co-lever. Diet and ApoB-lowering drugs are complementary rather than competing. The robust, low-controversy conclusion is to shift toward a plant-predominant, minimally processed dietary pattern, with food quality mattering more than the plant-versus-animal label alone.

Methods. We conducted a structured narrative review of randomized controlled trials (RCTs), prospective cohorts, meta-analyses, controlled nonhuman-primate experiments, and society guidelines. We separate the evidence for dietary causation from the evidence for regression of established plaque, rank dietary patterns on two independent evidence ladders (imaging and hard events) under an explicit GRADE-informed scheme (Table 1), and analyze plaque composition, lumen, and arterial remodeling as distinct phenomena.

Keywords: coronary atherosclerosis; apolipoprotein B; plaque regression; arterial remodeling; dietary patterns; plant-based diet; Mediterranean diet; cardiovascular prevention.

Figure 1. The ApoB pathway from diet to coronary events. Diet is the major modifiable lifelong determinant of the ApoB-containing-lipoprotein burden, with exercise and lipid-lowering pharmacotherapy acting as complementary levers on the same node. Retained ApoB particles seed a lipid-rich necrotic core; the event-relevant change is in plaque composition and remodeling, which imaging — not lumen diameter — captures. This figure also serves as the graphical abstract.

1.  Introduction

For most of the twentieth century, the management of coronary artery disease (CAD) was palliative: relieve angina, treat infarction, and slow an assumed inexorable decline. That framing has been overturned. Atherosclerosis begins with the retention of ApoB-containing lipoproteins in the arterial intima. Retained particles undergo multiple modifications, provoke inflammatory and immune responses, and contribute to macrophage foam-cell formation and, in advanced lesions, the development of a lipid-rich necrotic core.¹,⁹²,⁹³ Because the process is dynamic, it is in principle modifiable: lipid-lowering therapy can halt progression and produce modest average reductions in coronary atheroma volume, while anti-inflammatory therapy can reduce cardiovascular events without necessarily lowering LDL-C.⁴,⁹⁵,⁹⁶

This biology has generated an enduring question that patients and physicians both ask: which diet is best to reverse plaque and prevent heart attacks? The literature offers no shortage of confident answers. Advocates of ultra-low-fat whole-food plant-based (WFPB) eating point to angiographic “reversal”; advocates of the Mediterranean pattern point to large randomized trials with fewer deaths. Each camp tends to present its preferred pattern as the singular gold standard.

We argue that the confident single-diet answer is an artifact of a methodological error: conflating plaque imaging endpoints with hard clinical endpoints, and conflating the magnitude of a reported effect with the quality of the evidence behind it. A diet that lowers a surrogate marker in a small unblinded study is not thereby proven to prevent death; a diet that prevents death has not thereby been shown to shrink a coronary lesion. We therefore build two independent evidence ladders — one for plaque regression, one for hard events — grade certainty separately with an explicit scheme, and only then integrate. Our specific question is deliberately narrower than “what is the healthiest lifestyle”: it is which dietary pattern, isolated as far as the evidence allows from physical activity and from lipid-lowering drugs, most favorably changes coronary plaque and events — recognizing that the best pattern will be the one that complements, rather than replaces, exercise and pharmacotherapy (§6). The intended readership is both the educated public and the practicing clinician.

2.  Methods and interpretive framework

2.1  Evidence sources and search

MEDLINE/PubMed, the Cochrane Library, and major guideline repositories were searched through the manuscript preparation date using combinations of terms for coronary atherosclerosis, plaque regression, coronary angiography, intravascular ultrasound, coronary CT angiography, Mediterranean diet, vegetarian and vegan diet, Portfolio diet, DASH, low-fat diet, ketogenic diet, and cardiovascular events. Reference lists of included reviews and trials were hand-searched. Study selection and certainty judgments were performed by a single author; this is a structured narrative review and critical appraisal, not a registered systematic review, and it was not adjudicated in duplicate.

We prioritized, in descending order: RCTs with clinical or validated imaging endpoints; systematic reviews and meta-analyses of RCTs; large prospective cohorts; and consensus guidelines from the American Heart Association (AHA), American College of Cardiology (ACC), European Society of Cardiology (ESC), and Cochrane Collaboration. Mechanistic and animal data were used to explain, never to establish, clinical effect. Blogs, advocacy pages, and commercial or partisan websites were excluded from evidence grading. Databases were searched from inception through the manuscript preparation date (mid-2026); no language restriction was applied. Consistent with a narrative-review design, screening was performed by the single author without duplicate adjudication, no formal PRISMA flow or quantitative pooling was undertaken, and risk of bias was appraised narratively at the study level (randomization, blinding, endpoint directness, intervention isolation, and precision) rather than with a formal instrument. These features are stated plainly because they bound the strength of every inference that follows and are themselves a limitation (§12).

2.2  Why two ladders, not one score

Six endpoint families recur in this field: ApoB / LDL particle concentration; endothelial function (flow-mediated dilation); systemic inflammation (high-sensitivity C-reactive protein, hs-CRP); carotid intima-media thickness (IMT) and carotid plaque; coronary plaque burden and composition (by quantitative coronary angiography [QCA], intravascular ultrasound [IVUS], or coronary computed tomography angiography [CCTA]); and hard events (myocardial infarction [MI], stroke, cardiovascular [CV] death, all-cause mortality). These are correlated but not commensurable. Lowering blood pressure or hs-CRP is not the same as regressing a coronary lesion, and changing carotid thickness is not the same as preventing infarction. Collapsing them into a single ranking is the central error this review avoids. Ladder A ranks patterns by evidence that they regress plaque on imaging (coronary and carotid kept separate); Ladder B ranks patterns by evidence that they reduce hard events. Within each ladder, ordering follows evidence quality, not raw effect size.

2.3  Certainty grading

We applied a GRADE-informed judgment separately on each ladder, using the explicit definitions in Table 1. These ratings represent an author-derived, GRADE-informed framework rather than a formal GRADE assessment; randomization, endpoint directness, sample size, precision, risk of bias, intervention isolation, consistency, and replication were considered together, and no single limitation automatically determined the final rating.

A worked example makes the logic reproducible: DISCO-CT and the Ornish trial are both randomized, both multicomponent, and both use surrogate imaging endpoints, yet DISCO-CT is graded low while the diet-alone effect in Ornish is graded very low — because DISCO-CT is larger, contemporary, and uses direct plaque-composition imaging (CCTA-measured noncalcified plaque) with a between-group comparison, whereas the Ornish signal is a small, older, lumen-based (QCA) endpoint in which diet is even less separable from the co-interventions. The same rule downgrades any uncontrolled series (e.g. Esselstyn) to very low regardless of effect size, because an adherence comparison cannot estimate a treatment effect. Applying these criteria consistently, rather than any single automatic disqualifier, is what distinguishes a low from a very-low rating throughout. For multicomponent lifestyle interventions we grade two distinct questions separately: certainty that the complete bundled program caused the imaging change, and certainty that diet itself caused it (see Table 2). A fuller treatment would provide a study-level risk-of-bias table rather than one global label per category. Across the field, three tiers emerge: dietary plaque-regression evidence is generally very-low-to-low certainty (small, unblinded, multicomponent, surrogate); Mediterranean hard-event evidence is low-to-moderate certainty; and lipid-lowering drug evidence is high certainty for events and moderate-to-high for imaging. This asymmetry is stated up front so that no dietary claim is mistaken for drug-level proof. The two-ladder structure and these ratings constitute an author-derived interpretive framework, not an objective scoring system or a formal GRADE assessment.

Table 1. Certainty-grading scheme applied to both evidence ladders (GRADE-informed).

Certainty	Definition used in this review
High	Multiple consistent, adequately powered randomized trials with validated endpoints, or a large meta-analysis of such trials.
Moderate	Randomized evidence with meaningful limitations (imprecision, indirectness, single trial, or unblinding).
Low	Small randomized trials, or strong and consistent observational evidence.
Very low	Case series, uncontrolled studies, multicomponent interventions in which the exposure of interest cannot be isolated, severe risk of bias, or substantial imprecision.

3.  Diet as the major modifiable determinant of coronary atherosclerosis

Before comparing dietary patterns as treatments, it is worth establishing what the disease is. A large and internally consistent body of human population evidence indicates that coronary atherosclerosis is not an inevitable consequence of aging but a disease whose lifetime incidence tracks lifelong exposure to atherogenic, ApoB-raising diets. This distinction matters for everything that follows: coronary atherosclerosis is primarily driven by cumulative exposure to ApoB-containing lipoproteins, and diet is the major modifiable lifelong determinant of that exposure in most populations — so diet is also the principal modifiable lifelong lever in most populations, while pharmacotherapy is best understood as a potent downstream correction of a burden that diet shapes upstream. Monogenic and non-dietary drivers (familial hypercholesterolemia, PCSK9 gain-of-function, LDLR and APOB variants, lipoprotein(a), chronic kidney disease, inflammatory disorders, diabetes, and smoking) can each raise ApoB or accelerate disease independently of diet, which is why diet is framed here as the major modifiable determinant rather than the sole cause.

3.1  Migrant cohorts separate genes from environment

The most decisive population evidence comes from migrant studies, because they hold genetic background approximately constant while diet and environment change. The Ni-Hon-San study examined about 11,900 men of Japanese ancestry in Japan, Hawaii, and California using shared methods. Age-adjusted definite coronary heart disease (CHD) prevalence rose across the gradient — approximately 5.3, 5.2, and 10.8 per 1,000 respectively — with a roughly two- to three-fold higher CHD risk in the US cohorts, tracking a parallel Japan-to-California rise in serum cholesterol and in dietary total and saturated fat. The gradient reflects broad westernization rather than diet in isolation — physical activity, body weight, smoking, blood pressure, and social environment all shifted in parallel — so it is best read as strong support for a diet-and-lipoprotein pathway rather than proof of a purely dietary cause; the diet-specific inference rests on its convergence with the individual-level and genetic evidence below.¹¹²,¹¹³ Because the migrating population was genetically stable, the gradient is difficult to attribute to genetics and points instead to diet-driven lipoprotein change as an operative cause. This is one of the strongest natural experiments available in human nutrition epidemiology.

3.2  Cross-cultural and cohort gradients converge

The Seven Countries Study measured serum cholesterol and diet in 16 cohorts and followed CHD mortality for decades. Absolute CHD death rates differed roughly two- to eight-fold across cohorts, lowest in the Mediterranean and Japanese cohorts and highest in northern Europe and the United States, tracking average saturated-fat intake and serum cholesterol; at 25 years the cohort-level relationship between mean cholesterol and CHD mortality was strong.¹¹⁴,¹¹⁵ The China–Cornell–Oxford project documented very low CHD rates in rural Chinese counties with low animal-food intake and low plasma cholesterol,¹¹⁶ and the Adventist Health Study-2 found the lowest all-cause and cardiovascular mortality among plant-predominant (notably pesco-vegetarian) eating patterns within a single well-characterized population.¹¹⁷

Ecological and cohort comparisons are, by themselves, a limited grade of causal evidence: confounding, measurement error, and the ecological fallacy all apply, and naive cross-population cholesterol–CHD correlations weaken when change over time and competing risks are modeled.¹¹⁴ The causal weight here does not rest on any single correlation. It rests on convergence: the migrant design controls for genetics; the individual-level associations within cohorts run the same direction as the between-cohort gradients; and human genetic (Mendelian-randomization) evidence independently establishes that lifelong lower ApoB-containing-lipoprotein exposure causes lower coronary risk (§7.1). When several methods that fail in unrelated ways all point the same way, the combined case for dietary causation is far stronger than any one of them alone.

3.3  What the causal argument does and does not establish

This evidence is powerful for causation and prevention: lifelong low-ApoB dietary exposure is associated with near-absence of clinical coronary disease, which implies the disease is largely preventable at its dietary root. It speaks less directly to the separate question of how far an already-established lesion in a mid-life adult can be reversed by diet — a different clock, addressed in §5. Keeping these two questions distinct is essential: proving that diet prevents a lifetime of disease is not the same as proving it reverses a decades-old plaque, and conflating them has been a recurring error in both advocacy and critique.

4.  Ladder A — Evidence for favorable change in atherosclerotic imaging

This ladder ranks dietary patterns by the quality of evidence that they produce favorable change on validated arterial imaging. A caution runs through it: the modalities do not measure the same thing. Quantitative coronary angiography (QCA) measures the vessel lumen, not plaque directly, so a change in luminal stenosis can arise from remodeling, vasomotor tone, or measurement variability as well as from plaque change; intravascular ultrasound (IVUS) and coronary computed tomography angiography (CCTA) measure atheroma volume and composition; and carotid intima-media thickness (IMT) is a distinct surrogate. To prevent readers from equating these endpoints, we organize the evidence by modality: coronary stenosis (QCA), coronary plaque burden (IVUS), coronary plaque composition (CCTA), carotid IMT and plaque, and the pharmacologic benchmark.

4.1  What each imaging modality measures — and why it matters for the lumen

Ladder A draws on several imaging modalities that are routinely conflated but measure fundamentally different things; distinguishing them is essential to interpreting every regression claim, and especially any statement about the lumen.

• Coronary angiography / quantitative coronary angiography (QCA). A two-dimensional silhouette of the contrast-filled lumen only; it does not image the vessel wall or the plaque. It reports minimal lumen diameter (MLD) and percent-diameter stenosis (%DS), and because it sees only the channel it systematically understates mural plaque and is blind to outward remodeling.
• Intravascular ultrasound (IVUS). A catheter-based cross-section of the full vessel wall; it quantifies atheroma volume (percent and total atheroma volume, PAV/TAV) and the external elastic membrane, so it measures remodeling directly. Virtual-histology IVUS estimates composition (fibrous, necrotic core, calcium).
• Optical coherence tomography (OCT). Near-histologic resolution (~10 µm); the best tool for fibrous-cap thickness and the microstructural features that predict rupture. Intensive lipid lowering thickens the cap on serial OCT.¹³⁴
• Near-infrared spectroscopy (NIRS). Quantifies lipid-core burden (the lipid-core burden index, LCBI), usually combined with IVUS on a hybrid catheter.
• Coronary CT angiography (CCTA). Non-invasive; images both lumen and wall and characterizes composition, including low-attenuation (lipid-rich) plaque, which can regress with intensive therapy independently of calcium.¹³³ The related coronary-artery-calcium (CAC/Agatston) score quantifies only the calcified — that is, the most stable — component.
• Magnetic resonance imaging (MRI). A research modality for carotid and coronary composition and inflammation.

The practical consequence, developed in §8.2, is that lumen-based modalities (angiography and QCA) and calcium-only measures (CAC) are the weakest readouts of plaque health: a large, dangerous burden can hide behind a near-normal lumen through outward (positive) remodeling, and a healing, de-lipidated plaque can show an unchanged or even smaller lumen through reverse (constrictive) remodeling. Wall- and composition-based modalities (IVUS, OCT, NIRS, CCTA) track the event-relevant change — lipid depletion and fibrous-cap stabilization — that a lumen silhouette misses. This is why, throughout Ladder A, we keep the modality attached to every result rather than speaking of “imaging” generically: a coronary regression claim means little until one knows which instrument produced it.

4.2  Coronary stenosis — quantitative coronary angiography (QCA)

Strongest historical regression signal: the Lifestyle Heart Trial (Ornish)

The Lifestyle Heart Trial remains the only randomized lifestyle trial demonstrating regression of coronary stenosis using invasive QCA. Forty-eight patients with moderate-to-severe CAD were randomized to an intensive multicomponent program centered on a roughly 10%-fat vegetarian diet (which permitted egg whites and limited nonfat dairy), combined with aerobic exercise, stress management, smoking cessation, and group psychosocial support, or to usual care.⁷⁸ At one year, average percent-diameter stenosis in the experimental group fell from 40.0% to 37.8%, while controls progressed from 42.7% to 46.1%; among more severe lesions the divergence was larger, and most treated lesions showed improvement in measured stenosis. The trial reported improvement in angiographically measured coronary stenosis, not direct quantification of plaque volume.⁷ At five years, regression continued in the experimental group while controls worsened further, and the control group experienced substantially more recurrent cardiac events than the intervention group over the follow-up period, as reported in the original trial.⁸

Interpretation. This is a landmark result, but the intervention is irreducibly multicomponent: diet cannot be separated from exercise, stress reduction, and smoking cessation. It is best described as an intensive multicomponent lifestyle program centered on a very-low-fat vegetarian or plant-predominant diet, and it should not be read as direct evidence for a strictly vegan, oil-free whole-food plant-based diet. With 48 patients, an unblinded design, and a surrogate (QCA) endpoint, certainty that diet specifically produced the angiographic improvement is very low — even though the effect size is arresting.

Esselstyn whole-food plant-based series

Esselstyn’s work is frequently cited as plaque “reversal,” but the 2014 report is an uncontrolled case series of 198 self-referred patients counselled to an oil-free WFPB diet as an adjunct to usual care (including statins). Among the 177 (89%) adherent patients over a mean 3.7 years, a single recurrent event was reported (0.6%), versus adverse events in 13 of 21 (62%) non-adherent patients. The adherent and non-adherent groups cannot be interpreted as treatment and control groups, and the 0.6% versus 62% contrast should not be treated as an estimate of dietary efficacy: adherence itself is influenced by illness, health literacy, prognosis, socioeconomic circumstances, medication adherence, and ability to remain in follow-up, and the counted endpoints may include revascularizations driven by clinical decision-making and surveillance rather than spontaneous events alone.⁹ These are outcome data, not systematic imaging data, and a comparison of adherent versus non-adherent patients cannot estimate a treatment effect: it is confounded by severe self-selection and adherer bias. Certainty for regression specifically: very low.

4.3  Coronary plaque burden — intravascular ultrasound (IVUS)

No dietary trial has used IVUS to demonstrate coronary plaque regression. The IVUS evidence base is pharmacologic and is discussed as the benchmark in §4.6. This gap is itself informative: the modality that most precisely quantifies coronary atheroma volume has never been deployed in an adequately powered diet trial.

4.4  Coronary plaque composition — coronary CT angiography (CCTA)

Most rigorous contemporary randomized imaging study: DISCO-CT

The most methodologically rigorous currently available randomized lifestyle-imaging trial incorporating a DASH dietary intervention is DISCO-CT. Ninety-two patients with nonobstructive CAD were randomized to a DASH diet plus increased physical activity plus optimal medical therapy (OMT), or OMT alone, with CCTA repeated after roughly 16 months.¹³ The intervention group showed a greater within-group reduction in CCTA-measured noncalcified plaque volume than controls (−51.3 mm³ versus −21.3 mm³; the between-group difference, not the within-group change, is the causal estimate of interest), and percent atheroma volume rose in controls but not in the intervention arm; these associations remained statistically significant after adjustment for body mass, cholesterol, and calcium score.¹³

Interpretation. Statistical adjustment cannot establish causality, and the bundled intervention (diet plus exercise), single-center setting, and modest sample size prevent attribution specifically to diet; noncalcified plaque is itself a heterogeneous tissue category rather than a single high-risk phenotype. Nonetheless this is a genuinely randomized coronary CCTA signal for a plant-forward, sodium-conscious pattern. Certainty: low — the highest on the dietary side of this ladder, which is why DISCO-CT is presented as the most rigorous currently available imaging study even though the Ornish trial carries the larger historical signal.

4.5  Ketogenic diets and marked ApoB elevation

No controlled clinical trial has demonstrated coronary plaque regression with a ketogenic dietary pattern. Interest has centered on lean, metabolically healthy people whose LDL-C rises markedly (often ≥190 mg/dL) on carbohydrate restriction — “lean-mass hyper-responders.” The KETO-CTA study reported one-year coronary CT angiography in such individuals; its published paper emphasized percent atheroma volume, and the authors subsequently clarified the pre-registered primary endpoint, a pooled median increase in noncalcified plaque volume of +18.9 mm³ (42.8% relative; mean +31.5 mm³, SD 31.5), with marked heterogeneity.¹⁴,¹⁵ That paper was later retracted by the journal after an expression of concern.¹⁴ More important than the publication history is the design: the cohort was uncontrolled and self-selected, so it does not establish the independent effects of diet, ApoB concentration, exposure duration, or participant selection, and its comparisons with other cohorts were descriptive. These reports should therefore be regarded as hypothesis-generating rather than as evidence that ketogenic diets either cause or prevent coronary plaque progression. The clinically important point is unaffected: in patients with established coronary disease, marked and sustained elevation of ApoB-containing lipoproteins is inconsistent with current evidence-based lipid-management principles.

4.6  Pharmacologic benchmark — the standard diet must be judged against

No dietary trial has produced coronary plaque regression matching the magnitude and rigor of high-intensity lipid-lowering therapy. In GLAGOV (a randomized, placebo-controlled, blinded trial; n=968), adding the PCSK9 inhibitor evolocumab to a statin drove time-weighted LDL-C to 36.6 mg/dL (versus 93.0 mg/dL) and changed percent atheroma volume (PAV) by −0.95% versus +0.05% on statin alone (a between-group difference of approximately −1.0 percentage point, P<0.001, as reported in the trial’s primary-endpoint table), with plaque regression in 64.3% versus 47.3% of patients.⁴ SATURN (randomized, active-comparator; n≈1,039) showed PAV regression of −1.22% on high-dose rosuvastatin,⁵ ASTEROID (open-label, single-arm) showed −0.98% PAV regression with a median TAV reduction of ~6.8%,⁶ and REVERSAL showed high-intensity statin therapy halts progression relative to moderate therapy.⁶⁹ Collectively, these multicenter intravascular-ultrasound (IVUS) studies — whose designs ranged from randomized active-comparator or placebo-controlled trials to an open-label single-arm study — provide consistent evidence that intensive LDL lowering can halt progression and produce modest average reductions in coronary atheroma volume, although a portion of the imaging change reflects plaque stabilization and calcification rather than volume loss alone.⁷⁰ Certainty for modest coronary atheroma regression is moderate-to-high; the evidence that intensive lipid lowering slows progression and produces modest regression is substantially stronger and more reproducible than the corresponding dietary evidence. This is the yardstick against which every dietary regression claim must be measured — and none reach it.

4.7  Carotid endpoints (surrogate; kept separate from coronary)

In the CORDIOPREV carotid substudy, the Mediterranean diet reduced common-carotid IMT at five years (−0.027 mm; P<0.001) and seven years (−0.031 mm; P<0.001) and reduced carotid plaque maximum height, whereas a low-fat diet produced no change.¹⁶ A PREDIMED sub study showed favorable change in internal-carotid IMT with a Mediterranean diet enriched with nuts.¹⁷ These represent favorable changes in carotid IMT and selected plaque measurements rather than demonstrated coronary plaque regression: carotid IMT may also reflect medial hypertrophy rather than focal atherosclerotic plaque — increasingly the preferred interpretation — and the carotid bed is in any case a surrogate for, not a measurement of, coronary disease.

Table 2. Ladder A — evidence for favorable change in atherosclerotic imaging, organized by modality. For multicomponent lifestyle interventions, certainty is graded separately for the complete bundled program and for the independent effect of diet.

Intervention	Endpoint / modality	Key result	Certainty: bundled	Certainty: diet alone
Benchmark: high-intensity statin ± PCSK9 inhibitor	Coronary PAV/TAV (serial IVUS)	Modest mean PAV reduction; regression in a majority of treated participants (GLAGOV placebo-controlled; SATURN active-comparator; ASTEROID single-arm)	MOD–HIGH	n/a (drug)
Intensive multicomponent lifestyle, very-low-fat vegetarian/plant-predominant diet (Ornish)	Coronary % stenosis (invasive QCA — lumen, not plaque)	Improved angiographic stenosis vs progression in controls; only randomized lifestyle QCA trial	LOW	VERY LOW
DASH + exercise + OMT (DISCO-CT) — most rigorous contemporary imaging RCT	Coronary noncalcified plaque (CCTA)	Between-group difference in NCPV change favoring intervention; single-center; n=92	LOW	VERY LOW
WFPB adjunct (Esselstyn)	Clinical events (uncontrolled case series)	0.6% vs 62% adherent vs non-adherent; not comparable groups; severe selection bias	VERY LOW	VERY LOW
Ketogenic diet in hyper-responders (KETO-CTA)	Coronary noncalcified plaque (CCTA)	Uncontrolled cohort; NCPV increased (+18.9 mm³ median); paper retracted; hypothesis-generating	N/A	N/A
Carotid surrogate: Mediterranean diet (CORDIOPREV, PREDIMED)	Carotid IMT / plaque height	IMT −0.027 to −0.031 mm; carotid ≠ coronary	LOW–MOD	LOW–MOD

5.  Ladder B — Evidence for reducing hard cardiac events

This ladder ranks dietary patterns by the strength of evidence that they reduce MI, stroke, CV mortality, and all-cause mortality. Here the ordering is dominated by large randomized trials and long prospective cohorts. Where possible we report event counts, absolute and relative effects, follow-up duration, and number needed to treat (NNT), because relative risk reductions are routinely overestimated when absolute effects are omitted.

5.1  Mediterranean-style diets — strongest randomized evidence among named dietary patterns

The Mediterranean pattern — rich in extra-virgin olive oil, vegetables, legumes, nuts, fish, and whole grains — has a coherent body of trial, cohort, and mechanistic evidence linking it to lower cardiovascular risk through effects on lipids, blood pressure, endothelial function, and inflammation.⁸⁰,⁹¹,⁹²,⁹⁸,⁹⁹ CORDIOPREV is the strongest recent secondary-prevention diet trial. One thousand and two patients with established CAD were randomized to a Mediterranean or a low-fat diet for seven years on top of OMT. Major adverse cardiovascular events occurred at 28.1 versus 37.7 per 1,000 person-years (87 versus 111 first events), an adjusted hazard ratio of approximately 0.74 (95% CI 0.54–0.96), a 25–28% relative reduction. A larger point estimate was reported in men than women, but this should be read as subgroup estimates rather than a demonstrated statistical interaction by sex.¹⁰

PREDIMED is the largest primary-prevention diet trial. Among 7,447 high-risk adults randomized to a Mediterranean diet supplemented with extra-virgin olive oil or nuts versus a low-fat control, the composite of MI, stroke, or CV death fell by roughly 28–30% (olive-oil arm HR 0.70, 95% CI 0.54–0.92; nut arm HR 0.72, 95% CI 0.54–0.96) over a median 4.8 years; the absolute between-group separation was small (on the order of a few primary events per 1,000 person-years, an approximate figure rather than an arm-specific rate), reflecting the primary-prevention setting.¹¹,⁷¹ Prespecified PREDIMED analyses also showed reduced incident diabetes and favorable cardiometabolic risk-factor changes, supporting biological plausibility, and meta-analyses of adherence cohorts are directionally concordant.⁷²,⁷³,⁷⁴,⁷⁵,⁷⁶

A necessary disclosure. The original 2013 PREDIMED report was retracted in 2018 after baseline-distribution screening revealed randomization irregularities affecting about 21% of participants (household members assigned as units; one site randomizing clinics rather than individuals). The trial was reanalyzed and republished, and the effect estimates were essentially unchanged.¹¹,¹⁸ This lowers certainty without overturning the result. The Lyon Diet Heart Study, an earlier secondary-prevention trial of a Mediterranean pattern enriched with alpha-linolenic acid, reported a large reduction in cardiac death and non-fatal MI (14 versus 44 events; adjusted risk ratios 0.28–0.53), though with small event numbers and older methodology.¹²

The cautious anchor. The 2019 Cochrane review of Mediterranean-style diets rated the certainty of evidence for clinical endpoints as low to moderate, concluding that meaningful uncertainty remains. ¹⁹ This is the essential corrective to over-claiming: the Mediterranean event evidence is the best available among named dietary patterns, but it is not drug-level proof. Its primacy here reflects that randomized outcome trials have been performed for the Mediterranean pattern and not, at comparable scale, for whole-food plant-based diets; the absence of such trials for WFPB is not evidence that it is biologically inferior, only that it has not been tested to the same endpoint.

5.2  Replacing saturated fat with unsaturated fat

Older pooled trials and the 2017 AHA Presidential Advisory on Dietary Fats estimated a potentially substantial reduction in coronary events — on the order of 25–30% under sustained substitution — when saturated fat was replaced with polyunsaturated vegetable oil, whereas later systematic reviews, including Cochrane, generally found a more modest reduction in combined cardiovascular events and greater uncertainty for cardiovascular and total mortality.²⁰,⁷⁷,⁷⁸ The supporting dietary trials are older and considerably less uniform than modern pharmacologic outcome trials. Replacing saturated fat with refined carbohydrate produced no benefit; replacement with whole grains modestly lowered risk.²¹ This substitution is one mechanistic bridge among several that unite the winning patterns (§5). Carbohydrate quality is equally decisive — whole-grain and low-glycemic sources behave very differently from refined starch and sugar — and the specific food source of a given fat further modifies risk, as large multinational cohorts of macronutrient intake illustrate.⁷⁹,⁸⁴,⁹⁰,⁹⁷

5.3  Healthful plant-based, Portfolio, and vegetarian patterns (cohorts)

Food quality within plant-based eating is decisive. In pooled analyses of more than 200,000 US health professionals, a healthful plant-based diet index was associated with lower coronary heart disease (HR 0.75; 95% CI 0.68–0.83), whereas an unhealthful plant-based index (refined grains, sugary drinks, sweets) was associated with higher risk (HR 1.32; 95% CI 1.20–1.46).²² “Plant-based” is not automatically protective. Consistent with this, higher intakes of nuts, dietary fiber, and fruit and vegetables, and lower intakes of red and processed meat, are each associated with lower cardiovascular risk in dose-response meta-analyses.⁸¹,⁸²,⁸³,⁸⁵,⁸⁶,⁸⁷,⁸⁸,⁸⁹ The Portfolio diet — viscous fiber, plant protein, nuts, and phytosterols — lowers LDL-C and ApoB substantially, ²³,²⁴ and higher adherence was associated with lower CV disease across three cohorts (HR ~0.86).²⁵

In the Adventist Health Study-2 (n=73,308), pesco-vegetarians demonstrated the lowest mortality estimate (HR 0.81; 95% CI 0.69–0.94), while vegan (HR 0.85; 95% CI 0.73–1.01) and lacto-ovo vegetarian (HR 0.91; 95% CI 0.82–1.00) groups generally showed numerically lower risks, although the vegan interval crossed unity for all-cause mortality and subgroup analyses varied by sex, with the associations more robust in men.²⁶,²⁷ The mechanism is consistent with the ApoB pathway: within the same cohort, vegans had the lowest BMI, the lowest prevalence of hypertension, and the most favorable total- and LDL-cholesterol profiles of any Adventist dietary group, and the older Adventist Health Study-1 lineage first linked vegetarian eating to markedly lower ischemic-heart-disease mortality (roughly a third lower in vegetarian men).¹³⁵ These remain observational associations subject to healthy-user bias, but their direction and lipid mediation align with the causal ApoB argument of §3. Randomized and observational syntheses consistently show that vegetarian and plant-based patterns lower LDL-C and ApoB, providing a plausible lipid pathway for these associations.⁹³,⁹⁴,⁹⁵,⁹⁶

An important observation. EPIC-Oxford followed 48,188 people for 18 years. Vegetarians had 22% lower ischemic heart disease (HR 0.78; 95% CI 0.70–0.87) but 20% higher total stroke (HR 1.20; 95% CI 1.02–1.40), driven by hemorrhagic stroke.²⁸ The higher observed hemorrhagic-stroke rate warrants attention to nutrient adequacy and stroke subtypes, but as an observational finding it does not establish causation or demonstrate that including fish prevents hemorrhagic stroke. All cohort estimates are observational and subject to healthy-user bias.

5.4  DASH — strongest for blood pressure

The DASH feeding trial lowered blood pressure by about 5.5/3.0 mmHg overall and 11.4/5.5 mmHg in hypertensive participants, without weight loss;²⁹ sodium reduction is additive.³⁰ DASH’s hard-event evidence is largely indirect, mediated through blood pressure, which is why it ranks as a superb risk-factor pattern rather than a proven hard-endpoint one; observational cohorts do associate DASH adherence with lower CV events.³¹

5.5  What failed, and what is unproven

A generic low-fat prescription did not deliver: in the Women’s Health Initiative Dietary Modification Trial (n=48,835 postmenopausal women, ~8 years), the dietary-modification intervention did not significantly reduce coronary heart disease (HR 0.94; 95% CI 0.86–1.02), stroke, or total cardiovascular disease, though adherence and achieved dietary separation were modest and it tested one specific program rather than every lower-fat diet.³² Critically, participants were not asked to replace saturated with unsaturated fat — consistent with the AHA advisory’s emphasis on substitution rather than mere fat reduction. Time-restricted eating currently lacks randomized evidence demonstrating coronary plaque regression or reduction in cardiovascular events, and cannot presently be recommended for those endpoints.³³

Table 3. Ladder B — dietary evidence for reducing hard cardiac events, graded by evidence quality.

Pattern	Best evidence	Key effect	Certainty
Mediterranean / pesco-Mediterranean	RCTs (CORDIOPREV, PREDIMED, Lyon)	~25–30% MACE reduction, primary & secondary prevention	LOW–MOD
Saturated-fat-for-PUFA replacement	Pooled RCTs (AHA advisory)	~25–30% CVD reduction under sustained substitution; older, less uniform trials	LOW–MOD
Healthful plant-based / Portfolio / vegetarian	Large cohorts (Satija, Glenn, AHS-2)	CHD HR 0.75; CVD HR ~0.86; lowest mortality estimate in pesco-vegetarians	LOW
DASH	Feeding trials; cohorts	BP −5.5/3.0 (−11.4/5.5 in hypertensives); events indirect	LOW–MOD (BP)
Generic low-fat	RCT (WHI)	No significant CHD/stroke/CVD reduction	MOD (null)
Time-restricted eating	No plaque/MACE RCTs	No randomized evidence for plaque regression or event reduction	INSUFFICIENT

5.6  The pharmacologic benchmark for events

As on the plaque ladder, dietary event evidence must be read against the pharmacologic standard, for which certainty is high. The Cholesterol Treatment Trialists’ meta-analyses (>170,000 participants) show that each 1.0 mmol/L (~39 mg/dL) reduction in LDL-C lowers major vascular events by about 21–22%; across the LDL-C ranges and follow-up periods represented in randomized trials, proportional event reduction has generally tracked the absolute reduction in LDL-C, without identification of a clear efficacy threshold within those studied ranges — a distinct proposition from proof of identical incremental benefit or of safety at every achievable concentration.³⁴,³⁵ IMPROVE-IT (n=18,144) showed that adding ezetimibe to a statin further reduced events (32.7% versus 34.7%; HR 0.936; P=0.016), confirming benefit from non-statin LDL lowering.³⁶ The PCSK9-inhibitor outcome trials FOURIER (evolocumab, n=27,564; HR 0.85, 95% CI 0.79–0.92)³⁷ and ODYSSEY Outcomes (alirocumab, n=18,924; primary composite HR 0.85, 95% CI 0.78–0.93; a nominal reduction in all-cause mortality was also observed, HR 0.85, 95% CI 0.73–0.98, interpreted cautiously given the trial’s hierarchical testing plan)³⁸ extend the causal chain to the lowest achieved LDL-C levels. High-certainty evidence therefore exists for CV event reduction with lipid lowering, while IVUS/CCTA studies provide moderate-to-high certainty for modest coronary plaque regression — a distinction the dietary literature cannot yet match on either axis.

6.  Exercise and vascular remodeling

Physical activity is not a minor lifestyle footnote in coronary disease. It is a determinant powerful enough to track the near-absence of the disease in the most active human populations, and powerful enough to reshape plaque morphology in ways that complicate every lumen-based reading. This section treats exercise as a distinct lever — parallel to diet and to pharmacotherapy — and is candid that its relationship to coronary plaque is genuinely double-edged: it modestly lowers the atherogenic-lipoprotein burden and drives plaque toward a more stable phenotype, yet in its most extreme forms it is associated with more coronary calcium, not less.

6.1  Exercise as an ApoB and metabolic co-lever

The populations with the lowest recorded coronary atherosclerosis are also the most physically active. Among the Tsimane of the Bolivian Amazon — a subsistence population combining habitual high physical activity with an unprocessed, low-saturated-fat diet — 85% of adults aged 40 or older had no coronary artery calcium and mean LDL-C sat in the 70–90 mg/dL range, the lowest coronary-disease burden yet reported in any population; the investigators attributed this to low lifetime LDL, low blood pressure, low glucose, normal body weight, non-smoking, and abundant activity acting together, and explicitly noted that the relative contribution of each remains undetermined.¹²⁸ Aerobic training itself modestly lowers ApoB-containing lipoproteins and improves the ApoB/ApoA-I ratio, with larger and more consistent effects on triglycerides, HDL sub-fractions, blood pressure, insulin sensitivity, visceral adiposity, and cardiorespiratory fitness.¹²⁹ Its ApoB effect is real but smaller than that of dietary saturated-fat replacement or of lipid-lowering pharmacotherapy; much of exercise’s benefit runs through leanness, insulin sensitivity, and endothelial function, and it converges with plant-rich diets on nitric-oxide bioavailability.⁴⁸,⁴⁹ On the ApoB axis, then, exercise is a genuine co-lever — and, through leanness, a determinant of ApoB secretion — rather than a bystander.

6.2  The athlete paradox: more calcium, but a more stable plaque

The pharmacologic imaging trials already establish the biological template: intensive lipid lowering depletes the lipid-rich compartment and thickens the fibrous cap while leaving the lumen little changed — percent-atheroma-volume regression in GLAGOV,⁴ low-attenuation (lipid-rich) plaque regression in EVAPORATE,¹³³ and cap thickening with smaller lipid cores in PACMAN-AMI¹³⁴ — so compositional stabilization without luminal gain is the expected signature of a healing artery, not an anomaly. The athlete data extend this template in an unexpected direction.

Here the double edge must be stated plainly, because it cuts against a naive “exercise reduces plaque” claim. Lifelong high-volume endurance training is associated not with less coronary plaque but, paradoxically, with more coronary-artery calcium than in matched, less-active controls. Merghani and colleagues found coronary plaque in 44% of masters male athletes versus 22% of controls,¹³⁰ and Aengevaeren and colleagues described a U-shaped relationship in which the highest lifetime exercise volumes carried the highest calcium scores.¹³¹ The decisive qualifier is compositional: the athletes’ plaques were predominantly calcified (roughly three-quarters in the Merghani cohort) rather than lipid-rich — a denser, more stable, less rupture-prone morphology that Baggish and Levine termed “hearts of stone.”¹³² The more recent Master@Heart study complicates even this reassuring reading: lifelong endurance athletes had more plaque of essentially every type — calcified, non-calcified, and mixed — not only stable calcified plaque, so the “hallmark of stability” interpretation should be held tentatively.¹³⁸ Event rates in these athletes nonetheless remain low, consistent with stability, and perhaps flow reserve, outweighing burden. The honest reading is therefore not that exercise shrinks plaque — measured calcium may rise — but that it shifts plaque toward a stabilized, calcified, rupture-resistant phenotype while modestly lowering ApoB. That is a narrower and more defensible claim than “exercise reverses plaque,” and it depends entirely on distinguishing burden from composition (§4.1): a rising calcium score in an athlete more plausibly reflects healing and stabilization than dangerous progression, which is precisely why a calcium-only endpoint is a poor guide to risk in this group.

6.3  Why exercise complicates the lumen — and why that reinforces this review’s method

Exercise bears directly on the lumen question this review keeps returning to. An athlete intuitively wants a wider lumen for flow, and the physics reward it steeply: by Poiseuille’s law, flow scales with the fourth power of radius, so a 10% larger radius carries roughly 46% more flow. But luminal caliber is governed by remodeling, not by plaque burden alone (§8.2): outward (positive) Glagov remodeling can preserve or even enlarge the lumen while plaque accumulates,¹²⁶ and reverse (constrictive) remodeling can shrink the lumen as a plaque heals. An athlete’s reassuring lumen may therefore coexist with substantial — if stable — burden, and a genuinely healing plaque may show an unchanged or smaller lumen. Exercise also widens the lumen dynamically through endothelial nitric-oxide-mediated vasodilation during exertion, a flow-reserve gain independent of resting anatomic caliber. The lesson is the one that structures Ladder A: exercise’s vascular benefit is captured by composition and flow reserve, not by lumen silhouette.

6.4  Exercise as a co-lever, not the isolated variable of this review

This is also why the strongest human diet-imaging signals cannot be attributed to diet alone. The Ornish program bundled a very-low-fat, plant-predominant diet with aerobic exercise, stress management, and smoking cessation; DISCO-CT bundled a DASH diet with increased physical activity (§4). In both, exercise is a component of the intervention, not a controlled-for covariate — which is why Ladder A grades a bundled certainty and a diet-alone certainty separately (Table 2), the device by which physical activity, and where present pharmacotherapy, are held analytically apart from diet. No data-driven apportionment of the diet-versus-exercise-versus-drug share of the observed effects is available from these bundled trials; any numerical split would be assumption-driven. The aim of this review therefore remains the isolated dietary contribution — which dietary pattern, considered on its own, most favorably changes plaque and events — with exercise and pharmacotherapy as complementary co-levers. On that criterion the plant-forward, Mediterranean-style core identified throughout is also the pattern that best sustains an active, lean phenotype: it supports a healthy body weight and imposes no barrier to the physical activity that independently lowers ApoB. The strongest lifestyle is neither diet instead of exercise nor exercise instead of diet, but the plant-forward diet that makes an active, lean life easiest to sustain — with lipid-lowering pharmacotherapy added whenever the ApoB target is not reached.

7.  Mechanistic basis — established versus overstated

7.1  The established lever: ApoB-containing lipoproteins

The initiating step in atherogenesis is retention of ApoB-containing lipoproteins in the arterial intima.¹² Each circulating LDL, IDL, VLDL, and lipoprotein(a) particle contains one ApoB-100 molecule, while intestinal remnant particles contain one ApoB-48 molecule; plasma ApoB therefore approximates the concentration of circulating atherogenic lipoproteins and is increasingly regarded as superior to LDL-C in discordance analyses.³⁹,⁴⁰ Mendelian randomization confirms ApoB as a principal causal driver of coronary disease, and recent large analyses continue to affirm ApoB particle number as the dominant lipid determinant of coronary risk, reinforced by the 2019 ESC/EAS position that ApoB is a more accurate risk marker than LDL-C. ApoB is nonetheless one causal factor among several: contemporary prevention frameworks treat atherogenic-lipoprotein burden, blood pressure, smoking, diabetes, adiposity, and inflammation as acting together, and the emphasis on ApoB here reflects its centrality to the diet-plaque question rather than a claim that it is the sole driver of coronary risk.¹³⁶⁴¹,⁴² Lowering ApoB-containing lipoproteins pharmacologically reduces cardiovascular events and can produce modest average coronary atheroma regression; dietary patterns that lower ApoB are biologically aligned with this causal pathway, although direct evidence that diet-induced ApoB reduction independently produces coronary plaque regression is limited.⁴³⁴

7.2  Dietary mechanisms are multiple, not solely LDL-receptor upregulation

Depending on composition, energy balance, weight change, and baseline metabolic status, these dietary patterns may influence ApoB and cardiovascular risk through several overlapping pathways, not all of which are demonstrated uniformly for every pattern or established at the level of human coronary endpoints. Replacing saturated with unsaturated fat can lower ApoB partly by up-regulating hepatic LDL-receptor expression,²⁰,⁴³ but this is not the only proposed route. Successful dietary patterns may also act through reduced hepatic cholesterol synthesis; reduced intestinal cholesterol absorption (augmented by plant sterols); increased fecal bile-acid excretion via viscous fiber, which can deplete the hepatic cholesterol pool and up-regulate the LDL receptor secondarily;²³,⁴⁴ reduced hepatic VLDL production; short-chain fatty acids from fiber fermentation that are proposed to modulate hepatic lipid handling;⁴⁵ and improvements in insulin sensitivity, adiposity, and hepatic fat that may lower atherogenic lipoprotein secretion — a weight-and-metabolic axis that is itself event-relevant, as SELECT showed pharmacologic weight loss reducing major cardiovascular events by about 20% in non-diabetic patients, largely independently of glycemic change.¹³⁷⁴⁶,⁴⁷ Endothelial function may also improve with plant-rich, polyphenol- and nitrate-containing diets through enhanced nitric-oxide bioavailability.⁴⁸,⁴⁹

7.3  Mechanisms the popular literature overstates

Several mechanisms invoked to condemn all animal foods are biologically interesting but not established as human coronary plaque drivers, and they should not anchor dietary recommendations:

• Trimethylamine-N-oxide (TMAO). TMAO is associated with cardiovascular and renal outcomes, but causal interpretation remains uncertain because kidney function, diet, microbiome composition, metabolic disease, and reverse causation can all influence circulating concentrations. Available human genetic and intervention evidence has not established that lowering circulating TMAO itself reduces coronary events; it may nonetheless remain a useful risk biomarker even if it proves not to be causal.⁵⁰,⁵¹
• Neu5Gc / xenosialitis. Compelling in humanized-mouse models, but not established as a human coronary plaque mechanism; absence of established proof does not exclude possible human relevance.⁵²,⁵³
• Dietary advanced glycation end-products and heme iron. Hypothesis-generating; human clinical plaque and event evidence is weak.⁵⁴,⁵⁵

Presenting these as settled causal pathways outruns the evidence. The defensible dietary case rests on ApoB, blood pressure, and food quality — not on these contested pathways.

7.4  ApoB entry and subendothelial retention — a second, barrier-side lever

The mechanisms above act mainly on the circulating concentration of ApoB. A complementary determinant of atherogenesis is the retention of those particles in the arterial wall, which is the defining initiating process. Atherosclerosis initiates when ApoB-containing lipoproteins are retained in the subendothelial intima through electrostatic binding between basic arginine and lysine residues on ApoB and negatively charged glycosaminoglycan chains on arterial proteoglycans — the well-established “response-to-retention” model.¹,⁶⁵,¹⁰³,¹⁰⁴ The amount retained depends on how many ApoB particles circulate, on their residence time and susceptibility to proteoglycan binding, and on how readily they enter the intima through endothelial transcytosis and junctional transport.

The endothelial glycocalyx — a luminal mesh of proteoglycans, glycosaminoglycans, and glycoproteins — contributes to this barrier. Experimental models indicate that an intact glycocalyx can limit endothelial permeability to LDL-sized particles and modulate transport through intercellular pathways, and that impaired glycocalyx barrier properties increase intimal LDL accumulation at atherosclerosis-prone sites such as arterial bifurcations.¹⁰⁵,¹⁰⁶,¹¹¹ Experimental and mechanistic evidence further suggests that glycocalyx disruption under disturbed-flow (low or oscillatory shear) conditions may contribute to focal endothelial permeability and atherosclerosis susceptibility at arterial bends and branch points.¹⁰⁷ Preserving glycocalyx integrity may therefore theoretically reduce ApoB entry, offering a cholesterol-independent route that could, in principle, complement the reduction of circulating ApoB — though reducing permeability alone has not been shown to carry clinical importance comparable with reducing circulating ApoB.

It must be emphasized, however, that this pathway is a mechanistic hypothesis, not a demonstrated route to plaque regression. The evidence that specific dietary plant nutrients (polyphenols, flavonoids, sulforaphane) protect the human glycocalyx is largely preclinical — cell-culture and animal models, or intermediate human endpoints such as flow-mediated dilation.¹⁰⁸,¹⁰⁹ The few randomized human glycocalyx trials used seaweed-derived supplements (glucosamine sulphate and fucoidan) and sublingual microvascular surrogates (perfused boundary region) in convalescent or comorbid populations, rather than whole-food diets or coronary imaging.¹¹⁰ No human data establish that diet-mediated glycocalyx protection regresses coronary plaque. Alongside plausible reductions in atherogenic remnants, blood pressure, and endothelial activation — each of which may influence ApoB entry and subendothelial retention — glycocalyx preservation is best presented as a hypothesis that could help explain benefits of plant-rich diets beyond ApoB-lowering, not as established fact. No dietary glycocalyx intervention has yet been shown to change a clinical or coronary-imaging endpoint, so this pathway remains a considerable distance from clinical translation and should not inform current recommendations.

8.  Plaque composition, lumen, and arterial remodeling

The debate over whether diet “reverses” plaque is usually confused because four different things are discussed as if they were one: the composition of the plaque (lipid-rich versus fibrous versus calcified), the total volume of the plaque, the size of the lumen, and the direction of arterial remodeling. These move on different timescales, respond differently to lowering ApoB, and are measured by different tools. Separating them clarifies both what regression realistically means and why the most clinically important change is not the one the older literature emphasized.

8.1  Two compartments: the regressible lipid core and the stubborn fibrocalcific scaffold

An atherosclerotic lesion is not one substance. Its lipid-rich, cellular, inflammatory compartment — foam cells, extracellular lipid, and the necrotic core — is metabolically active and comparatively rapidly clearable. Its fibrous (collagen) and calcified compartments are structural, slow to remodel, and in the case of dense calcification largely fixed. This distinction is decisive because the two compartments carry very different clinical risk: the lipid-rich, thin-capped, inflamed plaque is the one prone to rupture and to causing myocardial infarction, whereas densely calcified plaque is comparatively stable. Regressing the lipid compartment and thickening the fibrous cap is therefore not a lesser goal than shrinking a calcified stenosis — it is arguably the more important one.

The controlled primate literature demonstrates exactly this compartment-specific behavior, which is difficult to obtain in humans because it requires serial histology. When severe diet-induced hypercholesterolemia was reversed, the lipid compartment cleared first and most completely: cholesteryl esters and foam-cell lipid were depleted within months, necrotic-core debris resolved, and lesions became flatter, fibrotic, and lipid-poor.¹¹⁸,¹¹⁹,¹²⁰,¹²¹ Small and colleagues even observed a transient crystalline free-cholesterol phase during early regression — direct physicochemical evidence of lipid actively mobilizing out of the wall.¹²³ The fibrous and calcified components, by contrast, persisted; advanced, years-old lesions required sustained lipid lowering — in the long-term rhesus program, roughly 3.7 years — before intimal thickness and plaque area fell measurably, and dense calcification remained largely unchanged throughout.¹²²,¹²⁵

These monkeys were driven to serum cholesterols of roughly 400–700 mg/dL for many months and developed genuinely advanced, human-like coronary plaques with necrotic cores, fibrous caps, and calcification — not merely fatty streaks. The finding is therefore not that early lesions regress (they do), but the stronger and more relevant one that the lipid compartment of advanced lesions is mobilizable once the atherogenic lipoprotein burden is normalized. Crucially, regression occurred not only at extreme lipid reductions but at a plasma total-cholesterol ceiling near 200 mg/dL — a concentration attainable in humans — which directly addresses the objection that primate regression required non-physiological cholesterol swings.¹²¹,¹²²

8.2  Why the lumen is an unreliable readout: outward and constrictive remodeling

Arteries are not rigid tubes around a plaque; they remodel. Glagov’s landmark autopsy study of 136 human left-main coronary arteries showed that as plaque accumulates, the vessel initially enlarges outward, so that lumen cross-sectional area is approximately preserved until the lesion occupies roughly 40% of the area within the internal elastic lamina.¹²⁶ This outward (positive) remodeling means a large, dangerous plaque burden can coexist with a near-normal lumen and an almost normal angiogram — which is precisely why lumen-based imaging understates disease, and why a diet or drug that improves plaque without opening the lumen has still done something valuable. The opposite process, constrictive (negative) remodeling, also occurs: the arterial wall itself contracts, so the lumen narrows more than plaque volume alone would predict.¹²⁷

Remodeling makes lumen change an unreliable proxy for plaque health, and it cuts in both directions. In the primate regression studies, lipid lowering could roughly double coronary lumen and artery cross-sectional area via favorable outward remodeling and restored vasomotor function — even when the plaque’s own cross-sectional area did not shrink.¹²⁴ The lipid left, the cap stabilized, the endothelium recovered its capacity to dilate, and the usable channel widened — all clinically beneficial — without “shrinking the plaque” in the volumetric sense. Conversely, a plaque can regress in volume while the lumen barely changes because the wall remodels inward at the same time. The lesson is that lumen diameter and stenosis are red herrings as endpoints; composition and stability are what track risk. This is also why the field moved from angiographic stenosis to intravascular ultrasound and CT measures of plaque volume and composition.

8.3  Three distinct meanings of “regression”

Compositional regression — depletion of the lipid/necrotic core and thickening of the fibrous cap — is the fastest, largest, and most event-relevant change, and it is what both diet and drugs most reliably produce. Volumetric regression — the whole lesion getting smaller — is real but modest and slow by every route, including high-intensity drug therapy, where percent-atheroma-volume reductions on the order of 1% are typical (§4.6). Luminal change — the angiographic stenosis opening — is the least reliable, because it depends on which way the artery remodels. Much confusion in this field dissolves once these three are kept apart: the honest claim for diet-centered ApoB lowering is strong compositional regression and stabilization, modest volumetric regression, and variable luminal change — not dramatic stenosis reversal.

8.4  The human bridge: Ornish and Esselstyn read in this light

The two most cited human diet-centered programs fit this framework precisely, and their imperfections are best stated plainly. The Ornish Lifestyle Heart Trial provides the quantitative human lumen signal: using QCA in a randomized design, average percent-diameter stenosis improved in the intervention group and worsened in controls at one and five years, with fewer cardiac events, achieved through an intensive lifestyle program that did not mandate lipid-lowering drugs.⁸ That drug-independence is what makes Ornish the better source for the claim that diet-centered change alone can improve the coronary lumen. Its limitations are equally clear and were established earlier: it is a small, multicomponent program (diet plus exercise, stress management, and smoking cessation), so it cannot isolate diet; and its endpoint is angiographic, carrying exactly the remodeling-related unreliability described in §8.2. Its lumen finding should therefore be read as corroborating the direction of benefit, not as proof that stenosis reversal is the mechanism.

The Esselstyn’s series contributes the other endpoint — clinical events. Among adherent patients, the recurrent-event rate was strikingly low (a single event among 177 adherent patients over a mean 3.7 years), and the report includes illustrative individual angiograms showing lumen widening.⁹ Two honest qualifications are essential. First, most of Esselstyn’s patients were also taking lipid-lowering medication, so this is a diet-plus-statin program, not diet alone; the striking regression images should not be attributed to diet in isolation. Second, it is an uncontrolled adherence series in which adherent and non-adherent patients are not a treatment and a control group, so the event contrast overstates efficacy. Its value is not as a controlled trial but as a human observation that the event endpoint — the one least distorted by remodeling and lumen ambiguity — moved dramatically in the predicted direction.

8.5  Reading the evidence together

No single study here is decisive, and each is imperfect in a different way. But the streams fail independently and point the same direction, which is the circumstance under which convergent evidence becomes persuasive even when no one study is conclusive. The controlled primate experiments establish, with serial histology unobtainable in humans, that normalizing the ApoB-containing-lipoprotein burden regresses the lipid compartment of advanced coronary plaque and stabilizes it — at cholesterol levels humans can reach. Human genetics (§7.1) shows the same lipoprotein mechanism operates causally in people. The migrant and cohort epidemiology (§3) shows the dietary exposure produces the disease at the population level. The lipid-lowering imaging trials (§4.6) show that reducing ApoB in humans measurably de-lipidates and stabilizes plaque. And the human diet-centered programs — Ornish for lumen (an angiographic, lumen-based endpoint, not a direct measure of plaque) and events without mandated drugs, Esselstyn for events — show the predicted clinical signal, imperfectly measured but concordant.

Taken as a whole, these independent lines of evidence support a strong conclusion about direction and mechanism: diet-centered lowering of the ApoB-particle burden regresses the dangerous, lipid-rich, rupture-prone compartment of coronary plaque and stabilizes it, and this compositional change — not luminal reversal — is the principal way that both diet and drugs reduce events. They support only a moderate conclusion about magnitude in established human disease, and about how much is achievable by diet alone versus diet combined with pharmacotherapy, because the human diet-only regression data remain limited, multicomponent, and largely uncontrolled. Stated with that asymmetry — confident on direction and mechanism, appropriately hedged on magnitude and attribution — the diet-first thesis is on defensible ground: diet addresses the cause of the lipid burden continuously across a lifetime, drugs lower the same burden potently from mid-life onward.

9.  Integration — reading the evidence together

The ladders answer different questions, and their leaders differ. Intensive lifestyle programs centered on a plant-predominant diet lead the historical plaque ladder among diets; Mediterranean-style eating leads the events ladder. Two observations make an integrated recommendation possible.

First, among currently studied dietary patterns, a Mediterranean-style, plant-rich approach has the broadest combination of randomized clinical outcome evidence, favorable risk-factor effects, and supportive vascular imaging data. It reduces hard events in RCTs (Ladder B) and produces favorable changes in carotid IMT and selected plaque measures (Ladder A); its coronary imaging evidence, however, remains limited, so it should not be described as establishing coronary plaque regression. It can be nutritionally complete and acceptable to many patients. Second, every winning pattern converges on the same core — more vegetables, legumes, whole grains, nuts, fruit, and unsaturated fats; less red and processed meat, refined carbohydrate, and sodium excess. “Shift the diet toward a plant-predominant, minimally processed pattern” is the low-controversy, low-risk message that survives every caveat in this review. This is not in tension with the finding that Mediterranean-style eating has the strongest hard-outcome evidence: the two are largely the same recommendation viewed from different endpoints. Mediterranean patterns rank highest on Ladder B because they are what randomized outcome trials happened to test, not because they are mechanistically distinct — both the Mediterranean and whole-food plant-based patterns work chiefly by lowering the ApoB burden, and the lower-fat, plant-predominant end of that spectrum is where the (weaker) imaging-regression signal sits. We therefore recommend the shared plant-predominant core rather than a single branded pattern, and note that a clinician may reasonably implement it as either a Mediterranean or a whole-food plant-based diet depending on the patient’s risk profile, adherence, and preference.

Two dietary routes can implement this core, and they should not be conflated. Intensive multicomponent lifestyle programs centered on very-low-fat, plant-predominant diets provide the most prominent historical angiographic signal; whether a fully plant-based diet alone reproduces that effect is unknown, because the historical signal came from a multicomponent intervention using a vegetarian — not necessarily fully vegan — diet. A fully plant-based (WFPB) approach with appropriate supplementation (notably vitamin B₁₂, and attention to vitamin D, iodine, zinc, and long-chain omega-3 status) is a legitimate option for motivated patients when nutritionally adequate. Mediterranean-style dietary interventions provide the strongest randomized event evidence among the named dietary patterns reviewed. These interventions were predominantly plant-rich and commonly encouraged fish while limiting red and processed meat, but the trials did not isolate fish or any other single food as the source of benefit; a diet that includes fish is, by definition, not whole-food plant-based, and distinguishing these routes avoids a common category error.

Table 4. Integrated positioning of major dietary patterns across both ladders, with certainty and practical role.

Pattern	Plaque ladder (A)	Event ladder (B)	Practical role
Mediterranean-style, plant-rich pattern	Favorable carotid IMT change; coronary imaging limited	Strongest RCT evidence (low–mod)	Broadest evidence base across events and intermediate outcomes
Intensive multicomponent lifestyle, very-low-fat vegetarian/plant-predominant diet (Ornish)	Most prominent historical angiographic signal (very low for diet alone)	Suggestive; small/confounded	Historical proof-of-concept; diet not isolable
Fully plant-based / WFPB (supplemented)	No direct trial; not established to reproduce the Ornish signal alone	Cohort-level support only	Therapeutic option for motivated CAD patients
Portfolio	Little direct plaque data	Cohort event benefit; large ApoB drop	Targeted LDL/ApoB-lowering add-on
DASH	Coronary noncalcified plaque ↓ (DISCO-CT, low)	Strong for BP; events indirect	Blood-pressure-focused building block
Generic low-fat	Weak	Failed (WHI)	Not recommended as a standalone
Ketogenic (high-ApoB)	Progression signal	No benefit shown	Avoid for plaque reduction in CAD

10.  Special considerations

10.1  Protein and muscle in older adults

A common objection to plant-forward eating in older adults is sarcopenia. Current evidence does not demonstrate that animal protein is required for preservation of muscle in older adults: adequately dosed plant proteins – particularly soy or complementary protein blends — can support muscle maintenance when combined with sufficient total protein intake and resistance exercise.⁵⁶,⁵⁷ A 2025 systematic review did not detect a statistically significant muscle-mass advantage for animal protein in the subgroup aged 60 years or older; because the analysis was not designed as an equivalence or non-inferiority comparison, and given limited subgroup power and heterogeneity, this absence of a significant difference should not be read as proof that all plant and animal proteins are equivalent under all conditions. The same analysis found soy performed comparably to dairy and whey, whereas some isolated non-soy plant proteins provided less leucine or lower digestibility per gram, and no advantage translated into strength or physical-performance differences.⁵⁶ Athletes, older adults in energy deficit, and people recovering from illness may require individualized protein targets. By protein-quality scores (PDCAAS, DIAAS), soy scores close to dairy while some non-soy plant proteins score lower per gram, a gap offset by adequate total intake and blends. Practical planning should attend to total protein and its distribution across meals, individualized by body size, renal function, and training status, and to nutrients of concern on restrictive plant-based diets, including vitamin B₁₂, vitamin D, calcium, iodine, zinc, and omega-3 status.⁵⁸,⁵⁹

10.2  Diet is an adjunct, not a replacement

For established CAD, the highest-certainty plaque regression and event reduction come from guideline lipid-lowering therapy — high-intensity statin, with ezetimibe or a PCSK9 inhibitor as needed to reach ApoB/LDL targets.⁴,³⁴,³⁶,³⁷,³⁸,⁶⁰ The Mediterranean event benefit in CORDIOPREV was achieved on top of OMT, not instead of it.¹⁰ Current AHA/ACC and ESC prevention guidelines correspondingly position a healthy dietary pattern and guideline lipid-lowering therapy as complementary, not alternative, strategies.¹⁰⁰,¹⁰¹,¹⁰² Diet and drugs are complements; the best outcomes come from combining an ApoB-lowering dietary pattern with guideline pharmacotherapy.

11.  Bias and conflicts of interest

Two forms of bias pervade this field. Healthy-user bias and residual confounding inflate the observational estimates for vegetarian, Portfolio, and plant-based cohorts; people who choose these diets also smoke less, exercise more, and are of higher socioeconomic status.⁶¹ This is why even large, tight-CI cohorts cap at “low” certainty on Ladder B. Industry funding bias is documented rather than merely alleged: industry-related funding and sponsor-favorable conclusions have been documented in nutrition research, including studies involving sugar and sugar-sweetened beverages, with sponsored studies reaching sponsor-favorable conclusions several-fold more often than independent ones.⁶²,⁶³,⁶⁴ Documented conflicts should be disclosed and weighed, but distinguished from unproven allegations of intent, which have no place in a scientific review.

Applied to the specific trials weighed here, this consideration cuts in both directions and is stated openly. PREDIMED was funded by an independent public agency — the Spanish Instituto de Salud Carlos III — rather than by a commercial sponsor; however, the intervention foods were donated by the olive-oil and nut industries (extra-virgin olive oil from Hojiblanca and Patrimonio Comunal Olivarero; walnuts from the California Walnut Commission; almonds and hazelnuts from Borges and La Morella Nuts), and several lead investigators separately reported industry research grants and unpaid advisory roles, although the authors state the food sponsors had no part in trial design, analysis, or reporting. The pharmacologic imaging and outcome trials that anchor the drug comparison — among them GLAGOV, FOURIER, ODYSSEY OUTCOMES, and SELECT — were in turn designed and funded by the manufacturers of the agents tested (Amgen; Sanofi and Regeneron; Novo Nordisk). Neither the dietary nor the pharmacologic evidence base is free of commercial interest, and both should be weighed with that in view (§5).

12.  Limitations

• No head-to-head RCT compares WFPB, Mediterranean, and Portfolio patterns on either coronary plaque or hard events; the integrated positioning is a reasoned judgment across non-comparable trials, not a proven ordering.
• The strongest imaging trials (Ornish, DISCO-CT) are multicomponent, so the independent dietary effect cannot be isolated; statistical adjustment does not establish causation.
• PREDIMED’s retraction/republication and Cochrane’s cautious grading mean the Mediterranean event evidence, while best-in-class among diets, is not definitive.
• Cohort data cannot establish causation; effect magnitude is not the same as evidence strength.
• As a structured narrative review, this work did not follow a registered systematic-review protocol; selection of studies, while guided by an explicit source hierarchy, was not adjudicated in duplicate.
• Individualization matters: renal disease, diabetes, hypertension, sarcopenia risk, and adherence capacity should modulate the specific pattern chosen.

13.  Conclusions

Coronary atherosclerosis is primarily driven by cumulative exposure to ApoB-containing lipoproteins, with diet the major modifiable lifelong determinant in most populations. The strongest human population evidence — the genetically controlled Ni-Hon-San migrant gradient, corroborated by cross-cultural and cohort data and by human genetic evidence on ApoB-containing lipoproteins — supports diet as the major modifiable determinant of that exposure, and therefore as the principal modifiable lifelong lever against it. This is a causation-and-prevention conclusion of high confidence, and it should be distinguished from the separate, harder question of how far an established lesion can be reversed.

On reversal, the honest reading of the controlled primate experiments, the human lipid-lowering imaging trials, and the imperfect but concordant Ornish and Esselstyn data is that the dangerous, lipid-rich, rupture-prone compartment of coronary plaque is the most regressible one, and that normalizing the ApoB-particle burden depletes and stabilizes it — while dense fibrocalcific components persist. Because arteries remodel outward and inward, lumen and stenosis are unreliable endpoints; the event-relevant change is compositional stabilization, not luminal reversal. This supports a confident conclusion about direction and mechanism and a deliberately hedged one about magnitude in established human disease.

Diet and ApoB-lowering pharmacotherapy are therefore best understood not as competitors but as complementary levers on a single shared mechanism: diet addresses the atherogenic-lipoprotein burden at its source and across a lifetime, while statins and related agents lower the same burden potently from mid-life onward and carry the most reproducible human coronary-imaging data. In established disease the two are strongest together. Physical activity is a third lever on the same ApoB-and-metabolic axis, and the plant-forward pattern recommended here is precisely the one that best sustains the active, lean phenotype (§6); the aim throughout has been to isolate the dietary contribution, not to imply that diet substitutes for exercise or for guideline-directed pharmacotherapy. For the general public, the message that survives every caveat is simple, safe, and evidence-based: shift the diet toward whole plants – more vegetables, legumes, whole grains, nuts, and unsaturated fats; less red and processed meat and refined carbohydrate – as the principal modifiable, lifelong means of preventing the disease and, together with guideline-directed care, of treating it.

14.  Declarations

Funding. This review received no external funding.

Conflicts of interest. The author operates Curing Heart Disease, LLC, an educational platform on cardiovascular prevention. No industry funding supported this work.

Disclaimer. This article is for educational purposes and does not constitute individualized medical advice. Dietary and pharmacologic decisions should be made with a qualified clinician.

Institutional review board statement. Not applicable. This narrative review did not involve new studies of human or animal subjects.

Informed consent statement. Not applicable.

Data availability statement. No new data were created or analyzed in this study. Data sharing is not applicable.

Author contributions. P.M. conceived the review, performed the literature search and evidence grading, and wrote and revised the manuscript. The author has read and agreed to the published version of the manuscript.

Use of AI tools. AI-assisted tools were used to help draft and format the manuscript; the author reviewed, verified, and takes full responsibility for all content, including the accuracy of every citation.

Supplementary appendix: study-level grading rationale

This appendix records the certainty rating assigned to each principal body of evidence and the specific reasons for it, so that the judgments in Tables 2 and 3 are reproducible rather than opaque. Ratings follow the scheme in Table 1: a study or pattern is downgraded for non-randomized design, indirect or surrogate endpoints, imprecision, inability to isolate the exposure of interest, and risk of bias, and no single feature is automatically decisive.

Evidence body	Rating	Rationale for the rating
Lipid-lowering drugs — hard events (CTT, IMPROVE-IT, FOURIER, ODYSSEY)	HIGH	Multiple large, blinded, adequately powered RCTs with hard clinical endpoints and a consistent dose-response meta-analysis; no serious limitation.
Lipid-lowering drugs — coronary imaging (GLAGOV, SATURN, ASTEROID, REVERSAL)	MOD–HIGH	Randomized or active-comparator serial-IVUS trials with a direct plaque endpoint; downgraded only because part of the change reflects stabilization/calcification rather than volume loss.
Mediterranean diet — hard events (CORDIOPREV, PREDIMED, Lyon)	LOW–MOD	Randomized, hard endpoints; downgraded for unblinding, the PREDIMED randomization irregularity and republication, and Cochrane’s cautious grading.
SFA-for-PUFA replacement — events	LOW–MOD	Randomized substitution trials, but older, heterogeneous, and less uniform than modern outcome trials; imprecision for mortality.
Plant-based / Portfolio / vegetarian — events	LOW	Consistent large cohorts with a plausible ApoB mechanism, but observational and subject to healthy-user bias; no hard-endpoint RCT.
DASH — events	LOW–MOD (BP)	Strong randomized effect on blood pressure (a surrogate); hard-event evidence only indirect via cohorts.
DISCO-CT (DASH + activity) — coronary imaging	LOW	Randomized CCTA trial with a between-group plaque signal; downgraded for single-center setting, n=92, and multicomponent design. Highest on the dietary side of Ladder A.
Ornish (very-low-fat lifestyle) — coronary imaging	LOW bundled / VERY LOW diet-alone	Only randomized lifestyle QCA trial (bundled = low), but n=48, unblinded, lumen-based surrogate, and diet inseparable from exercise/stress/smoking change (diet-alone = very low).
Esselstyn WFPB series — events	VERY LOW	Uncontrolled adherence series; an adherent-vs-non-adherent comparison cannot estimate a treatment effect (referral, survivorship, adherer bias); most patients also on statins.
KETO-CTA (hyper-responders) — coronary imaging	N/A (hypothesis-generating)	Uncontrolled, self-selected cohort; cannot isolate diet, ApoB, or exposure duration; paper retracted. Not gradeable as evidence for or against progression.
Carotid surrogate (CORDIOPREV, PREDIMED substudies)	LOW–MOD	Randomized, but carotid IMT/plaque is a surrogate for, not a measure of, coronary disease and may reflect medial hypertrophy.

The recurring logic is visible across the table: randomization and a direct, hard endpoint raise certainty; surrogate endpoints, small or single-center samples, multicomponent bundling, observational design, and documented irregularities lower it. The two lowest tiers (very low, and not-gradable) are reserved for designs that cannot in principle estimate the effect of interest, independent of how large the reported effect appears.

References

1. Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524-533. doi:10.1038/s41586-021-03392-8
2. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14(5):575-585. doi:10.1016/j.cmet.2011.07.015
3. Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313-2330. doi:10.1093/eurheartj/ehz962
4. Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316(22):2373-2384. doi:10.1001/jama.2016.16951
5. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078-2087. doi:10.1056/NEJMoa1110874
6. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556-1565. doi:10.1001/jama.295.13.jpc60002
7. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990;336(8708):129-133. doi:10.1016/0140-6736(90)91656-u
8. Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998;280(23):2001-2007. doi:10.1001/jama.280.23.2001
9. Esselstyn CB Jr, Gendy G, Doyle J, Golubic M, Roizen MF. A way to reverse CAD?. J Fam Pract. 2014;63(7):356-364b.
10. Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet. 2022;399(10338):1876-1885. doi:10.1016/S0140-6736(22)00122-2
11. Estruch R, Ros E, Salas-Salvadó J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018;378(25):e34. doi:10.1056/NEJMoa1800389
12. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99(6):779-785. doi:10.1161/01.cir.99.6.779
13. Henzel J, Kępka C, Kruk M, et al. High-Risk Coronary Plaque Regression After Intensive Lifestyle Intervention in Nonobstructive Coronary Disease: A Randomized Study. JACC Cardiovasc Imaging. 2021;14(6):1192-1202. doi:10.1016/j.jcmg.2020.10.019
14. Soto-Mota A, Norwitz NG, Manubolu VS, et al. Longitudinal Data from the KETO-CTA Study: Plaque Predicts Plaque, ApoB Does Not: JACC Adv. 2025;4(7):101686 [retraction of: JACC Adv. 2025 Jul;4(7):101686. doi: 10.1016/j.jacadv.2025.101686.]. JACC Adv. 2026;5(5):102824. doi:10.1016/j.jacadv.2026.102824
15. Soto-Mota A, Norwitz NG, Manubolu VS, et al. Reply: The Keto CTA Study. JACC Adv. 2025;4(7):101862. doi:10.1016/j.jacadv.2025.101862
16. Jimenez-Torres J, Alcalá-Diaz JF, Torres-Peña JD, et al. Mediterranean Diet Reduces Atherosclerosis Progression in Coronary Heart Disease: An Analysis of the CORDIOPREV Randomized Controlled Trial. Stroke. 2021;52(11):3440-3449. doi:10.1161/STROKEAHA.120.033214
17. Sala-Vila A, Romero-Mamani ES, Gilabert R, et al. Changes in ultrasound-assessed carotid intima-media thickness and plaque with a Mediterranean diet: a substudy of the PREDIMED trial. Arterioscler Thromb Vasc Biol. 2014;34(2):439-445. doi:10.1161/ATVBAHA.113.302327
18. Estruch R, Ros E, Salas-Salvadó J, et al. Retraction and Republication: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med 2013;368:1279-90 [retraction of: N Engl J Med. 2013 Apr 4;368(14):1279-90. doi: 10.1056/NEJMoa1200303.]. N Engl J Med. 2018;378(25):2441-2442. doi:10.1056/NEJMc1806491
19. Rees K, Takeda A, Martin N, et al. Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2019;3(3):CD009825. Published 2019 Mar 13. doi:10.1002/14651858.CD009825.pub3
20. Sacks FM, Lichtenstein AH, Wu JHY, et al. Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. Circulation. 2017;136(3):e1-e23. doi:10.1161/CIR.0000000000000510
21. Li Y, Hruby A, Bernstein AM, et al. Saturated Fats Compared With Unsaturated Fats and Sources of Carbohydrates in Relation to Risk of Coronary Heart Disease: A Prospective Cohort Study. J Am Coll Cardiol. 2015;66(14):1538-1548. doi:10.1016/j.jacc.2015.07.055
22. Satija A, Bhupathiraju SN, Spiegelman D, et al. Healthful and Unhealthful Plant-Based Diets and the Risk of Coronary Heart Disease in U.S. Adults. J Am Coll Cardiol. 2017;70(4):411-422. doi:10.1016/j.jacc.2017.05.047
23. Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA. 2003;290(4):502-510. doi:10.1001/jama.290.4.502
24. Chiavaroli L, Nishi SK, Khan TA, et al. Portfolio Dietary Pattern and Cardiovascular Disease: A Systematic Review and Meta-analysis of Controlled Trials. Prog Cardiovasc Dis. 2018;61(1):43-53. doi:10.1016/j.pcad.2018.05.004
25. Glenn AJ, Guasch-Ferré M, Malik VS, et al. Portfolio Diet Score and Risk of Cardiovascular Disease: Findings From 3 Prospective Cohort Studies. Circulation. 2023;148(22):1750-1763. doi:10.1161/CIRCULATIONAHA.123.065551
26. Orlich MJ, Singh PN, Sabaté J, et al. Vegetarian dietary patterns and mortality in Adventist Health Study 2. JAMA Intern Med. 2013;173(13):1230-1238. doi:10.1001/jamainternmed.2013.6473
27. Kwok CS, Umar S, Myint PK, Mamas MA, Loke YK. Vegetarian diet, Seventh Day Adventists and risk of cardiovascular mortality: a systematic review and meta-analysis. Int J Cardiol. 2014;176(3):680-686. doi:10.1016/j.ijcard.2014.07.080
28. Tong TYN, Appleby PN, Bradbury KE, et al. Risks of ischaemic heart disease and stroke in meat eaters, fish eaters, and vegetarians over 18 years of follow-up: results from the prospective EPIC-Oxford study. BMJ. 2019;366:l4897. Published 2019 Sep 4. doi:10.1136/bmj.l4897
29. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336(16):1117-1124. doi:10.1056/NEJM199704173361601
30. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344(1):3-10. doi:10.1056/NEJM200101043440101
31. Salehi-Abargouei A, Maghsoudi Z, Shirani F, Azadbakht L. Effects of Dietary Approaches to Stop Hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases–incidence: a systematic review and meta-analysis on observational prospective studies. Nutrition. 2013;29(4):611-618. doi:10.1016/j.nut.2012.12.018
32. Howard BV, Van Horn L, Hsia J, et al. Low-fat dietary pattern and risk of cardiovascular disease: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295(6):655-666. doi:10.1001/jama.295.6.655
33. Lowe DA, Wu N, Rohdin-Bibby L, et al. Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity: The TREAT Randomized Clinical Trial. JAMA Intern Med. 2020;180(11):1491-1499. doi:10.1001/jamainternmed.2020.4153
34. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. doi:10.1016/S0140-6736(10)61350-5
35. Silverman MG, Ference BA, Im K, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-1297. doi:10.1001/jama.2016.13985
36. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-2397. doi:10.1056/NEJMoa1410489
37. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664
38. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107. doi:10.1056/NEJMoa1801174
39. Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019;4(12):1287-1295. doi:10.1001/jamacardio.2019.3780
40. Marston NA, Giugliano RP, Melloni GEM, et al. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. JAMA Cardiol. 2022;7(3):250-256. doi:10.1001/jamacardio.2021.5083
41. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144
42. Ference BA, Kastelein JJP, Ray KK, et al. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA. 2019;321(4):364-373. doi:10.1001/jama.2018.20045
43. Fernandez ML, West KL. Mechanisms by which dietary fatty acids modulate plasma lipids. J Nutr. 2005;135(9):2075-2078. doi:10.1093/jn/135.9.2075
44. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69(1):30-42. doi:10.1093/ajcn/69.1.30
45. Chambers ES, Preston T, Frost G, Morrison DJ. Role of Gut Microbiota-Generated Short-Chain Fatty Acids in Metabolic and Cardiovascular Health. Curr Nutr Rep. 2018;7(4):198-206. doi:10.1007/s13668-018-0248-8
46. Rosenzweig JL, Bakris GL, Berglund LF, et al. Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(9):3939-3985. doi:10.1210/jc.2019-01338
47. Barkas F, Bathrellou E, Nomikos T, Panagiotakos D, Liberopoulos E, Kontogianni MD. Plant Sterols and Plant Stanols in Cholesterol Management and Cardiovascular Prevention. Nutrients. 2023;15(13):2845. Published 2023 Jun 22. doi:10.3390/nu15132845
48. Lidder S, Webb AJ. Vascular effects of dietary nitrate (as found in green leafy vegetables and beetroot) via the nitrate-nitrite-nitric oxide pathway. Br J Clin Pharmacol. 2013;75(3):677-696. doi:10.1111/j.1365-2125.2012.04420.x
49. Storniolo CE, Casillas R, Bulló M, et al. A Mediterranean diet supplemented with extra virgin olive oil or nuts improves endothelial markers involved in blood pressure control in hypertensive women. Eur J Nutr. 2017;56(1):89-97. doi:10.1007/s00394-015-1060-5
50. Zhu W, Wang Z, Tang WHW, Hazen SL. Gut Microbe-Generated Trimethylamine N-Oxide From Dietary Choline Is Prothrombotic in Subjects. Circulation. 2017;135(17):1671-1673. doi:10.1161/CIRCULATIONAHA.116.025338
51. Jia J, Dou P, Gao M, et al. Assessment of Causal Direction Between Gut Microbiota-Dependent Metabolites and Cardiometabolic Health: A Bidirectional Mendelian Randomization Analysis. Diabetes. 2019;68(9):1747-1755. doi:10.2337/db19-0153
52. Samraj AN, Pearce OM, Läubli H, et al. A red meat-derived glycan promotes inflammation and cancer progression. Proc Natl Acad Sci U S A. 2015;112(2):542-547. doi:10.1073/pnas.1417508112
53. Alisson-Silva F, Kawanishi K, Varki A. Human risk of diseases associated with red meat intake: Analysis of current theories and proposed role for metabolic incorporation of a non-human sialic acid. Mol Aspects Med. 2016;51:16-30. doi:10.1016/j.mam.2016.07.002
54. Uribarri J, Woodruff S, Goodman S, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010;110(6):911-16.e12. doi:10.1016/j.jada.2010.03.018
55. Hunnicutt J, He K, Xun P. Dietary iron intake and body iron stores are associated with risk of coronary heart disease in a meta-analysis of prospective cohort studies. J Nutr. 2014;144(3):359-366. doi:10.3945/jn.113.185124
56. Reid-McCann RJ, Brennan SF, Ward NA, Logan D, McKinley MC, McEvoy CT. Effect of Plant Versus Animal Protein on Muscle Mass, Strength, Physical Performance, and Sarcopenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Nutr Rev. 2025;83(7):e1581-e1603. doi:10.1093/nutrit/nuae200
57. Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc. 2013;14(8):542-559. doi:10.1016/j.jamda.2013.05.021
58. Pawlak R, Parrott SJ, Raj S, Cullum-Dugan D, Lucus D. How prevalent is vitamin B(12) deficiency among vegetarians?. Nutr Rev. 2013;71(2):110-117. doi:10.1111/nure.12001
59. Bakaloudi DR, Halloran A, Rippin HL, et al. Intake and adequacy of the vegan diet. A systematic review of the evidence. Clin Nutr. 2021;40(5):3503-3521. doi:10.1016/j.clnu.2020.11.035
60. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625
61. Zeraatkar D, Cheung K, Milio K, et al. Methods for the Selection of Covariates in Nutritional Epidemiology Studies: A Meta-Epidemiological Review. Curr Dev Nutr. 2019;3(10):nzz104. Published 2019 Sep 17. doi:10.1093/cdn/nzz104
62. Lesser LI, Ebbeling CB, Goozner M, Wypij D, Ludwig DS. Relationship between funding source and conclusion among nutrition-related scientific articles. PLoS Med. 2007;4(1):e5. doi:10.1371/journal.pmed.0040005
63. Kearns CE, Schmidt LA, Glantz SA. Sugar Industry and Coronary Heart Disease Research: A Historical Analysis of Internal Industry Documents. JAMA Intern Med. 2016;176(11):1680-1685. doi:10.1001/jamainternmed.2016.5394
64. Bes-Rastrollo M, Schulze MB, Ruiz-Canela M, Martinez-Gonzalez MA. Financial conflicts of interest and reporting bias regarding the association between sugar-sweetened beverages and weight gain: a systematic review of systematic reviews. PLoS Med. 2013;10(12):e1001578. doi:10.1371/journal.pmed.1001578
65. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116(16):1832-1844. doi:10.1161/CIRCULATIONAHA.106.676890
66. Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340(2):115-126. doi:10.1056/NEJM199901143400207
67. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685-1695. doi:10.1056/NEJMra043430
68. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914
69. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071-1080. doi:10.1001/jama.291.9.1071
70. Puri R, Nicholls SJ, Shao M, et al. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol. 2015;65(13):1273-1282. doi:10.1016/j.jacc.2015.01.036
71. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet [retracted in: N Engl J Med. 2018 Jun 21;378(25):2441-2442. doi: 10.1056/NEJMc1806491.]. N Engl J Med. 2013;368(14):1279-1290. doi:10.1056/NEJMoa1200303
72. Salas-Salvadó J, Bulló M, Estruch R, et al. Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial. Ann Intern Med. 2014;160(1):1-10. doi:10.7326/M13-1725
73. Estruch R, Martínez-González MA, Corella D, et al. Retracted: Effect of a high-fat Mediterranean diet on bodyweight and waist circumference: a prespecified secondary outcomes analysis of the PREDIMED randomised controlled trial [retracted in: Lancet Diabetes Endocrinol. 2019 May;7(5):334. doi: 10.1016/S2213-8587(19)30073-7.]. Lancet Diabetes Endocrinol. 2016;4(8):666-676. doi:10.1016/S2213-8587(16)30085-7
74. Estruch R, Martínez-González MA, Corella D, et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med. 2006;145(1):1-11. doi:10.7326/0003-4819-145-1-200607040-00004
75. Schwingshackl L, Hoffmann G. Adherence to Mediterranean diet and risk of cancer: a systematic review and meta-analysis of observational studies. Int J Cancer. 2014;135(8):1884-1897. doi:10.1002/ijc.28824
76. Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr. 2010;92(5):1189-1196. doi:10.3945/ajcn.2010.29673
77. Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2010;7(3):e1000252. Published 2010 Mar 23. doi:10.1371/journal.pmed.1000252
78. Hooper L, Martin N, Jimoh OF, Kirk C, Foster E, Abdelhamid AS. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev. 2020;8(8):CD011737. Published 2020 Aug 21. doi:10.1002/14651858.CD011737.pub3
79. Dehghan M, Mente A, Zhang X, et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet. 2017;390(10107):2050-2062. doi:10.1016/S0140-6736(17)32252-3
80. Estruch R, Camafort M. The Mediterranean diet and plasma lipid profile. Rev Esp Cardiol (Engl Ed). 2015;68(4):279-281. doi:10.1016/j.rec.2014.11.021
81. Kris-Etherton PM, Hu FB, Ros E, Sabaté J. The role of tree nuts and peanuts in the prevention of coronary heart disease: multiple potential mechanisms. J Nutr. 2008;138(9):1746S-1751S. doi:10.1093/jn/138.9.1746S
82. Aune D, Keum N, Giovannucci E, et al. Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies. BMC Med. 2016;14(1):207. Published 2016 Dec 5. doi:10.1186/s12916-016-0730-3
83. Threapleton DE, Greenwood DC, Evans CE, et al. Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis. BMJ. 2013;347:f6879. Published 2013 Dec 19. doi:10.1136/bmj.f6879
84. Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet. 2019;393(10170):434-445. doi:10.1016/S0140-6736(18)31809-9
85. Anderson JW, Baird P, Davis RH Jr, et al. Health benefits of dietary fiber. Nutr Rev. 2009;67(4):188-205. doi:10.1111/j.1753-4887.2009.00189.x
86. Wang X, Ouyang Y, Liu J, et al. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. BMJ. 2014;349:g4490. Published 2014 Jul 29. doi:10.1136/bmj.g4490
87. Aune D, Giovannucci E, Boffetta P, et al. Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality-a systematic review and dose-response meta-analysis of prospective studies. Int J Epidemiol. 2017;46(3):1029-1056. doi:10.1093/ije/dyw319
88. Micha R, Wallace SK, Mozaffarian D. Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis. Circulation. 2010;121(21):2271-2283. doi:10.1161/CIRCULATIONAHA.109.924977
89. Zhong VW, Van Horn L, Greenland P, et al. Associations of Processed Meat, Unprocessed Red Meat, Poultry, or Fish Intake With Incident Cardiovascular Disease and All-Cause Mortality. JAMA Intern Med. 2020;180(4):503-512. doi:10.1001/jamainternmed.2019.6969
90. Wang DD, Li Y, Chiuve SE, et al. Association of Specific Dietary Fats With Total and Cause-Specific Mortality. JAMA Intern Med. 2016;176(8):1134-1145. doi:10.1001/jamainternmed.2016.2417
91. Wang X, Ouyang YY, Liu J, Zhao G. Flavonoid intake and risk of CVD: a systematic review and meta-analysis of prospective cohort studies. Br J Nutr. 2014;111(1):1-11. doi:10.1017/S000711451300278X
92. Widmer RJ, Flammer AJ, Lerman LO, Lerman A. The Mediterranean diet, its components, and cardiovascular disease. Am J Med. 2015;128(3):229-238. doi:10.1016/j.amjmed.2014.10.014
93. Yokoyama Y, Levin SM, Barnard ND. Association between plant-based diets and plasma lipids: a systematic review and meta-analysis. Nutr Rev. 2017;75(9):683-698. doi:10.1093/nutrit/nux030
94. Wang F, Zheng J, Yang B, Jiang J, Fu Y, Li D. Effects of Vegetarian Diets on Blood Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2015;4(10):e002408. Published 2015 Oct 27. doi:10.1161/JAHA.115.002408
95. Dinu M, Abbate R, Gensini GF, Casini A, Sofi F. Vegetarian, vegan diets and multiple health outcomes: A systematic review with meta-analysis of observational studies. Crit Rev Food Sci Nutr. 2017;57(17):3640-3649. doi:10.1080/10408398.2016.1138447
96. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003;77(5):1146-1155. doi:10.1093/ajcn/77.5.1146
97. Neuenschwander M, Barbaresko J, Pischke CR, et al. Intake of dietary fats and fatty acids and the incidence of type 2 diabetes: A systematic review and dose-response meta-analysis of prospective observational studies. PLoS Med. 2020;17(12):e1003347. Published 2020 Dec 2. doi:10.1371/journal.pmed.1003347
98. Chiva-Blanch G, Badimon L, Estruch R. Latest evidence of the effects of the Mediterranean diet in prevention of cardiovascular disease. Curr Atheroscler Rep. 2014;16(10):446. doi:10.1007/s11883-014-0446-9
99. Guasch-Ferré M, Willett WC. The Mediterranean diet and health: a comprehensive overview. J Intern Med. 2021;290(3):549-566. doi:10.1111/joim.13333
100. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi:10.1093/eurheartj/ehab484
101. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646. doi:10.1161/CIR.0000000000000678
102. Writing Committee, Lloyd-Jones DM, Morris PB, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80(14):1366-1418. doi:10.1016/j.jacc.2022.07.006
103. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15(5):551-561. doi:10.1161/01.atv.15.5.551
104. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116(16):1832-1844. doi:10.1161/CIRCULATIONAHA.106.676890
105. Mundi S, Massaro M, Scoditti E, et al. Endothelial permeability, LDL deposition, and cardiovascular risk factors-a review. Cardiovasc Res. 2018;114(1):35-52. doi:10.1093/cvr/cvx226
106. Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch. 2007;454(3):345-359. doi:10.1007/s00424-007-0212-8
107. Chen L, Qu H, Liu B, et al. Low or oscillatory shear stress and endothelial permeability in atherosclerosis. Front Physiol. 2024;15:1432719. Published 2024 Sep 9. doi:10.3389/fphys.2024.1432719
108. Cascajosa-Lira A, Prieto AI, Pichardo S, Jos A, Cameán AM. Protective effects of sulforaphane against toxic substances and contaminants: A systematic review. Phytomedicine. 2024;130:155731. doi:10.1016/j.phymed.2024.155731
109. Pavlidis G, Kountouri A, Katogiannis K, et al. Effects of 4-month treatment with glycocalyx dietary supplement on endothelial glycocalyx and vascular function after COVID-19 infection. Eur J Clin Invest. 2025;55(7):e70058. doi:10.1111/eci.70058
110. Cosgun ZC, Fels B, Kusche-Vihrog K. Nanomechanics of the Endothelial Glycocalyx: From Structure to Function. Am J Pathol. 2020;190(4):732-741. doi:10.1016/j.ajpath.2019.07.021
111. van den Berg BM, Spaan JA, Vink H. Impaired glycocalyx barrier properties contribute to enhanced intimal low-density lipoprotein accumulation at the carotid artery bifurcation in mice. Pflugers Arch. 2009;457(6):1199-1206. doi:10.1007/s00424-008-0590-6
112. Robertson TL, Kato H, Rhoads GG, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California. Incidence of myocardial infarction and death from coronary heart disease. Am J Cardiol. 1977;39(2):239-243. doi:10.1016/s0002-9149(77)80197-5
113. Kagan A, Harris BR, Winkelstein W Jr, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: demographic, physical, dietary and biochemical characteristics. J Chronic Dis. 1974;27(7-8):345-364. doi:10.1016/0021-9681(74)90014-9
114. Keys A, Menotti A, Karvonen MJ, et al. The diet and 15-year death rate in the seven countries study. Am J Epidemiol. 1986;124(6):903-915. doi:10.1093/oxfordjournals.aje.a114480
115. Verschuren WM, Jacobs DR, Bloemberg BP, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA. 1995;274(2):131-136.
116. Chen, J., Campbell, T.C., Li, J.Y., Peto, R., Boreham, J., Feng, Z., & Youngman, L.D. (1990). Diet life-style and mortality in China: a study of the characteristics of 65 Chinese counties.
117. Orlich MJ, Singh PN, Sabaté J, et al. Vegetarian dietary patterns and mortality in Adventist Health Study 2. JAMA Intern Med. 2013;173(13):1230-1238. doi:10.1001/jamainternmed.2013.6473
118. Armstrong ML, Warner ED, Connor WE. Regression of coronary atheromatosis in rhesus monkeys. Circ Res. 1970;27(1):59-67. doi:10.1161/01.res.27.1.59
119. Armstrong ML, Megan MB. Lipid depletion in atheromatous coronary arteries in rhesus monkeys after regression diets. Circ Res. 1972;30(6):675-680. doi:10.1161/01.res.30.6.675
120. Vesselinovitch D, Getz GS, Hughes RH, Wissler RW. Atherosclerosis in the rhesus monkey fed three food fats. Atherosclerosis. 1974;20(2):303-321. doi:10.1016/0021-9150(74)90015-x
121. Wagner WD, St Clair RW, Clarkson TB, Connor JR. A study of atherosclerosis regression in Macaca mulatta: III. Chemical changes in arteries from animals with atherosclerosis induced for 19 months and regressed for 48 months at plasma cholesterol concentrations of 300 or 200 mg/dl. Am J Pathol. 1980;100(3):633-650.
122. Clarkson TB, Bond MG, Bullock BC, McLaughlin KJ, Sawyer JK. A study of atherosclerosis regression in Macaca mulatta. V. Changes in abdominal aorta and carotid and coronary arteries from animals with atherosclerosis induced for 38 months and then regressed for 24 or 48 months at plasma cholesterol concentrations of 300 or 200 mg/dl. Exp Mol Pathol. 1984;41(1):96-118. doi:10.1016/0014-4800(84)90011-x
123. Small DM, Bond MG, Waugh D, Prack M, Sawyer JK. Physicochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis. J Clin Invest. 1984;73(6):1590-1605. doi:10.1172/JCI111366
124. Williams JK, Anthony MS, Honoré EK, et al. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol. 1995;15(7):827-836. doi:10.1161/01.atv.15.7.827
125. Strong JP, Bhattacharyya AK, Eggen DA, Malcom GT, Newman WP 3rd, Restrepo C. Long-term induction and regression of diet-induced atherosclerotic lesions in rhesus monkeys. I. Morphological and chemical evidence for regression of lesions in the aorta and carotid and peripheral arteries. Arterioscler Thromb. 1994;14(6):958-965. doi:10.1161/01.atv.14.6.958
126. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316(22):1371-1375. doi:10.1056/NEJM198705283162204
127. Pasterkamp G, Wensing PJ, Post MJ, Hillen B, Mali WP, Borst C. Paradoxical arterial wall shrinkage may contribute to luminal narrowing of human atherosclerotic femoral arteries. Circulation. 1995;91(5):1444-1449. doi:10.1161/01.cir.91.5.1444
128. Kaplan H, Thompson RC, Trumble BC, et al. Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study. Lancet. 2017;389(10080):1730-1739. doi:10.1016/S0140-6736(17)30752-3
129. Wood G, Taylor E, Ng V, et al. Estimating the Effect of Aerobic Exercise Training on Novel Lipid Biomarkers: A Systematic Review and Multivariate Meta-Analysis of Randomized Controlled Trials. Sports Med. 2023;53(4):871-886. doi:10.1007/s40279-023-01817-0
130. Merghani A, Maestrini V, Rosmini S, et al. Prevalence of Subclinical Coronary Artery Disease in Masters Endurance Athletes With a Low Atherosclerotic Risk Profile. Circulation. 2017;136(2):126-137. doi:10.1161/CIRCULATIONAHA.116.026964
131. Aengevaeren VL, Mosterd A, Braber TL, et al. Relationship Between Lifelong Exercise Volume and Coronary Atherosclerosis in Athletes. Circulation. 2017;136(2):138-148. doi:10.1161/CIRCULATIONAHA.117.027834
132. Baggish AL, Levine BD. Coronary Artery Calcification Among Endurance Athletes: “Hearts of Stone”. Circulation. 2017;136(2):149-151. doi:10.1161/CIRCULATIONAHA.117.028750
133. Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41(40):3925-3932. doi:10.1093/eurheartj/ehaa652
134. Räber L, Ueki Y, Otsuka T, et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327(18):1771-1781. doi:10.1001/jama.2022.5218
135. Matsumoto S, Beeson WL, Shavlik DJ, et al. Association between vegetarian diets and cardiovascular risk factors in non-Hispanic white participants of the Adventist Health Study-2. J Nutr Sci. 2019;8:e6. Published 2019 Feb 21. doi:10.1017/jns.2019.1
136. Morze J, Melloni GEM, Wittenbecher C, et al. ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease. Eur Heart J. 2025;46(27):2691-2701. doi:10.1093/eurheartj/ehaf207
137. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
138. De Bosscher R, Dausin C, Claus P, et al. Lifelong endurance exercise and its relation with coronary atherosclerosis. Eur Heart J. 2023;44(26):2388-2399. doi:10.1093/eurheartj/ehad152